Compare SFST & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SFST | CTNM |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.0M | 550.7M |
| IPO Year | 2012 | 2024 |
| Metric | SFST | CTNM |
|---|---|---|
| Price | $59.82 | $7.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $68.50 | $22.14 |
| AVG Volume (30 Days) | 60.5K | ★ 1.2M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 0.46 |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $6,282,000.00 | N/A |
| Revenue This Year | $23.97 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $40.91 | $7.72 |
| 52 Week High | $65.09 | $17.79 |
| Indicator | SFST | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 22.34 |
| Support Level | $58.50 | N/A |
| Resistance Level | $61.69 | $14.22 |
| Average True Range (ATR) | 1.14 | 1.15 |
| MACD | 0.04 | -0.52 |
| Stochastic Oscillator | 57.76 | 3.33 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.